Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202499 · ClinicalTrials.gov registry record · Early Phase 1
Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 86
- Enrollment target
NCT02202499 is a Early Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 86 participants.
The verdict
NCT02202499, a Early Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this Pilot feasibility study is to find out the effect of different behavioral treatments along with different duration of a drug called varenicline, on smoking behavior and quitting smoking. Varenicline, also known as Chantix™, is an FDA-approved medication that has been shown to help people quit smoking.
Interventions
- DRUG Varenicline
- OTHER Counseling and Support Materials
- OTHER Laboratory Assessments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2014-07-17 |
| Est. Completion | 2019-06-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02202499
The ClinicalTrials.gov registry entry for NCT02202499 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Varenicline is the first listed.
NCT02202499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02202499 about?
NCT02202499 is a clinical study titled "Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence". The purpose of this Pilot feasibility study is to find out the effect of different behavioral treatments along with different duration of a drug called varenicline, on smoking behavior and quitting smoking. Varenicline, also known as Chantix™, is an FDA-approved medication that has been shown to hel...
What is the current status of trial NCT02202499?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 86 participants. The study started on 2014-07-17. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT02202499?
The interventions under investigation include: Varenicline (DRUG), Counseling and Support Materials (OTHER), Laboratory Assessments (OTHER).
Who is sponsoring clinical trial NCT02202499?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.